Matthew Brown, PhD
@matt_brown04
Followers
184
Following
2K
Media
56
Statuses
1K
Research Fellow, Regeneron PhD: @IcahnMountSinai
Joined February 2013
I’m incredibly grateful for the support from @parkerici with this Early Career Researcher Award and excited for the opportunity to join this amazing network of investigators in the field of cancer immunology. Thank you also for the continued mentorship @BhardwajLab @SinaiImmunol
We proudly announce our 2023 Early Career Researcher awardees. Since 2016, PICI has provided more than $20 million in funding to train and empower the scientific leaders of tomorrow. Learn more:
2
3
19
Nature research paper: Parent-of-origin effects on complex traits in up to 236,781 individuals https://t.co/AdGl8JUkXg
nature.com
Nature - A novel multistep strategy reveals how parent-of-origin effects shape complex traits in large-scale biobanks.
2
10
52
An exciting summer highlight: @matt_brown04 successfully defended his thesis, “Neoantigen-specific surveillance intercepts precancerous MMR-deficient cells and governs immunotherapy response,” co-mentored by @rsamstein! A major milestone and a proud moment for the lab! 👏🎓
4
4
25
Nature research paper: Whole-genome sequencing of 490,640 UK Biobank participants https://t.co/Tdcx81Oa9f
nature.com
Nature - A study reports whole-genome sequences for 490,640 participants from the UK Biobank and combines these data with phenotypic data to provide new insights into the relationship between human...
1
78
267
Collection highlight from @Cancer_Cell: Mutant KRAS peptide targeted CAR-T cells engineered for cancer therapy https://t.co/b8gtAGEtKk
@PennMedicine
1
37
144
Stanford Medicine researchers have developed a lipid‑nanoparticle mRNA approach to engineer and track CAR‑T cells inside the body to eliminate cancer. https://t.co/81z9XlQmnY
med.stanford.edu
mRNA bundled in lipid nanoparticles trains T cells in mice to eliminate cancer. Coupled with noninvasive imaging, researchers tracked the in situ CAR-T cells to assess their effectiveness and safety.
4
28
63
A new Science #Immunology study identifies CD8 #Tcells with enhanced effector function in tumors, which could be leveraged for #cancer treatments. https://t.co/rEA3XGLwco
0
33
98
Experimental treatment could offer a safer, cheaper alternative to CAR T cell therapies for disorders such as lupus https://t.co/c8Y2SlOUEG
nature.com
Nature - Experimental treatment could offer a safer, cheaper alternative to CAR-T-cell therapies for disorders such as lupus.
2
37
127
A new study identifies a novel subset of mast cells that cross-present tumor antigens in triple-negative #breastcancer — and a pilot trial shows how these can be exploited in immunotherapy strategies. News & Views from Ignacio Melero et al @ClinicaNavarra
https://t.co/JhORbaVCc8
nature.com
Nature Medicine - A new study identifies a novel subset of mast cells that cross-present tumor antigens in patients triple-negative breast cancer — and a pilot clinical trial shows how these...
0
23
80
In Science, researchers present a new method to safely and preferentially generate CAR T cells directly inside the body using targeted lipid nanoparticles that deliver mRNA directly to T cells. The approach showed rapid and sustained immune reprogramming in preclinical models,
13
123
418
With the help of a technique called Massively Parallel Ribosome Profiling, researchers in Science have identified more than 4000 open reading frames—stretches of genetic material that can encode proteins—across 679 human-associated viral genomes. https://t.co/eKSTtWLZUd
10
68
204
A new Science #Immunology Review examines the multifaceted ways in which T follicular helper cells modulate immune responses during infection, #allergy, and #autoimmune diseases. https://t.co/gdVv4tTbJr
0
72
243
Spatial and multiomics analysis of human and mouse lung adenocarcinoma precursors reveals TIM-3 as a putative target for precancer interception https://t.co/AaJAvgxweT
1
29
105
What if engineered T cells could defeat AML—and persist long enough to prevent relapse? A new @NatureComms study led by PICI Investigator Philip Greenberg, MD & team at @fredhutch found WT1-specific TCR-T cells showed activity but often lost function—except when azacitidine
1
9
36
B cell-depletion mitigates MS symptoms but its effects on other immune cells was unclear David A. Hafler @yyoshiaki & team now show anti-CD20 therapy affects the amount and function of cerebral spinal fluid macrophages and circulating monocytes: https://t.co/2CyRzf3iXX
1
4
10
A clinical trial using engineered CAR-T cells to hunt cancer cells has reported impressive results for solid tumours https://t.co/ud4VsdL5kv
9
144
547
As presented at #ASCO25: Intracerebroventricular infusion of bivalent EGFR and IL13Rα2-targeting #CARTcells in patients with recurrent #glioblastoma was well tolerated with 1 patient with a partial response and 1 patient with durable stable disease
0
4
17
Online Now: The pan-cancer proteome atlas, a mass spectrometry-based landscape for discovering tumor biology, biomarkers, and therapeutic targets
4
92
312
Cancer of unknown primary site encompasses a heterogeneous group of metastatic cancers with an unidentified primary site of origin. Putative site-specific therapy and empirical chemotherapy are acceptable treatment options. Read the Clinical Practice article “Cancer of Unknown
6
139
422
New research in Science establishes #CRISPR-associated transposase (CAST) as a powerful platform technology for efficient, RNA-guided gene integration in human cells. https://t.co/l2ZhVjpcFz
10
71
196
Can personalized vaccines make immunotherapy more effective in bladder cancer? In a new Nature Cancer study, PICI investigator Nina Bhardwaj, MD, PhD, tested PGV001 + atezolizumab. All patients showed immune responses. 3 of 4 in the adjuvant group remained recurrence-free at 39
0
2
8